The opportunity to redefine the treatment of major diseases is what drives everyone at Vertex. Our development portfolio represents the fruit of these efforts. Spend some time here and look around. Click on the pipeline chart to get information on our development programs and links to selected published articles. Go further and see how, just maybe, disease challenges may be overcome with innovation.

VX-765
(Epilepsy)

VX-765 is a novel Caspase-1 inhibitor being investigated for the treatment of epilepsy.

VX-765 has been shown to inhibit acute seizures in preclinical models of acute epilepsy and has shown activity in preclinical models of chronic epilepsy that do not respond to standard anti-epileptic drugs.

Vertex is conducting a Phase 2 proof-of-concept clinical trial of VX-765 in patients with treatment-resistant epilepsy. The company completed enrollment of the trial in mid-2010 and expects to obtain interim clinical data in the second half of 2010.